A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease
- PMID: 12809076
A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease
Abstract
The male aging process brings about declines in hormonal function including a gradual decline in bioavailable testosterone levels. Animal studies suggest that testosterone modulates cognitive function through enhancing acetylcholine release and up-modulation of nicotinic receptors. Tau protein deposition is also affected by androgen supplementation in animals. We hypothesize that testosterone replacement in elderly hypogonadal males may improve cognition, in particular the visual-spatial domain. Thirty-six male patients with a new diagnosis of Alzheimer's disease had their total and bioavailable testosterone levels measured. None of the patients had been on acetylcholinesterase inhibitors. Ten of the 36 patients (28%) were deemed biochemically hypogonadal (total testosterone < 240 ng/dl or 7 nmol/l). Five of the hypogonadal patients were randomized to testosterone and five to placebo. Initial Alzheimer's Disease Assessment Scale cognitive subscale (ADAScog) and Mini Mental Status Examination (MMSE) ranged from 31 to 19 and from 17 to 22, respectively. The clock drawing test (CDT) and the pentagon-tracing portion of the MMSE were used as measures of visual-spatial abilities. Normal prostate-specific antigen (PSA) levels were essential before treatment with intramuscular testosterone, 200 mg every 2 weeks. Measurement of testosterone, complete blood count, lipids, PSA and neuropsychological cognitive tests were repeated at 3, 6, 9 and 12 months of treatment. In the testosterone-treated group, levels of total testosterone increased from a mean of 126.4 ng/dl to 341 ng/dl or 3.6 nmol/l to 9.7 nmol/l (p = 0.11). Bioavailable testosterone also increased from a mean of 48.7 ng/dl to 142 ng/dl or 1.39 nmol/l to 4.05 nmol/l (p = 0.10). PSA levels were also elevated from a mean of 0.98 to 1.37 ng/ml (p = 0.07). ADAScog improved from a mean of 25 to 16.3 (p = 0.02); MMSE improved from a mean of 19.4 to 23.2 (p = 0.02), CDT also improved from 2.2 to 3.2 (p = 0.07). One patient stopped treatment because of hypersexual behavior. The placebo-treated group deteriorated gradually. This small pilot study performed in aging male patients suggests that testosterone could indeed improve cognition, including visual-spatial skills in mild to moderate Alzheimer's disease.
Similar articles
-
Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.Int J Impot Res. 2008 Nov-Dec;20(6):561-5. doi: 10.1038/ijir.2008.40. Epub 2008 Oct 9. Int J Impot Res. 2008. PMID: 18843272
-
Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.BJU Int. 2009 May;103(9):1179-83. doi: 10.1111/j.1464-410X.2008.08240.x. Epub 2008 Dec 23. BJU Int. 2009. PMID: 19154450
-
Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.Int J Impot Res. 2008 Mar-Apr;20(2):213-7. doi: 10.1038/sj.ijir.3901618. Epub 2007 Sep 27. Int J Impot Res. 2008. PMID: 17898800 Clinical Trial.
-
Testosterone therapy: treatment of metabolic disturbances in heart failure.J Cardiovasc Pharmacol Ther. 2011 Mar;16(1):14-23. doi: 10.1177/1074248410378121. Epub 2010 Nov 19. J Cardiovasc Pharmacol Ther. 2011. PMID: 21097668 Review.
-
Testosterone levels and cognition in elderly men: a review.Maturitas. 2011 Aug;69(4):322-37. doi: 10.1016/j.maturitas.2011.05.012. Epub 2011 Jun 21. Maturitas. 2011. PMID: 21696899 Review.
Cited by
-
Trans-ethnic genomic informed risk assessment for Alzheimer's disease: An International Hundred K+ Cohorts Consortium study.Alzheimers Dement. 2023 Dec;19(12):5765-5772. doi: 10.1002/alz.13378. Epub 2023 Jul 14. Alzheimers Dement. 2023. PMID: 37450379
-
The Effect of Testosterone Replacement on Sexual Function in the Elderly: A Systematic Review and Meta-Analysis.World J Mens Health. 2023 Oct;41(4):861-873. doi: 10.5534/wjmh.220171. Epub 2023 Jan 4. World J Mens Health. 2023. PMID: 36649923 Free PMC article.
-
[Testosterone and Alzheimer's disease].Probl Endokrinol (Mosk). 2022 Jun 24;68(5):97-107. doi: 10.14341/probl13136. Probl Endokrinol (Mosk). 2022. PMID: 36337024 Free PMC article. Russian.
-
The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.Int J Mol Sci. 2022 Oct 8;23(19):11952. doi: 10.3390/ijms231911952. Int J Mol Sci. 2022. PMID: 36233256 Free PMC article. Review.
-
Serum clinical laboratory tests and risk of incident dementia: a prospective cohort study of 407,190 individuals.Transl Psychiatry. 2022 Aug 4;12(1):312. doi: 10.1038/s41398-022-02082-x. Transl Psychiatry. 2022. PMID: 35927253 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous